Table 4.
Detailed cost (Swedish kronor) and cost-effectiveness results of base-case analysis for women and men
| Cost item | Men | Women | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Candesartan | Losartan | Difference | Candesartan | Losartan | Difference | |
| Drug cost | 1831 | 723 | 1108 | 1833 | 725 | 1108 |
| Stroke-related | 53,814 | 55,407 | −1593 | 63,737 | 65,455 | −1718 |
| MI-related | 33,636 | 34,852 | −1216 | 38,963 | 40,267 | −1304 |
| CHD-related | 6243 | 6489 | −246 | 7260 | 7525 | −265 |
| Heart failure-related | 37,779 | 39,273 | −1494 | 44,843 | 46,474 | −1631 |
| Arrhythmia related | 3661 | 3806 | −145 | 4321 | 4478 | −157 |
| PAD-related | 19,202 | 19,876 | −674 | 22,275 | 23,000 | −725 |
| Total costs | 156,166 | 160,425 | −4259 | 183,233 | 187,925 | −4692 |
| Life years | 14.307 | 14.253 | 0.054 | 15.606 | 15.556 | 0.050 |
| QALYs | 11.138 | 11.081 | 0.057 | 11.218 | 11.165 | 0.053 |
| Cost per life-year gained | Dominant* | Dominant* | ||||
| Cost per QALY gained | Dominant* | Dominant* | ||||
Note:
*
Candesartan is associated with a gain in life years/QALYs and lower costs compared with losartan.
Abbreviations: CHD, coronary heart disease; PAD, peripheral arterial disease; MI, myocardial infarction; QALY, quality-adjusted life-years.